Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients ― A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study ―

Selexipag is an oral prostacyclin receptor (IP receptor) agonist with a non-prostanoid structure. This study examined its efficacy and safety in Japanese patients with non-operated or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).